Kiniksa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from devastating and debilitating diseases with significant unmet medical need. We have built a pipeline of product candidates across various stages of development, currently focused on autoinflammatory and autoimmune diseases. Kiniksa has initiated Rhapsody, a Phase 3 study to assess the efficacy and safety of rilonacept treatment in subjects with recurrent pericarditis. To learn more, visit www.kiniksa.com.
ACC.19 Learning Pathways? (select one) Interventional Cardiology